SPG20 siRNA (Human)

siRNA to inhibit SPG20 expression using RNA interference

• Supplier: Cohesion Biosciences
• Product #: CRH8005
• Source: Synthetic
• Reactivity: H
• Applications: RNAi
• Delivery Time: Ship in 1 week
• Specificity: SPG20 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Form: Lyophilized powder
• Gene Symbol: SPG20
• Alternative Names: KIAA0610; TAHCCP1; Spartin; Spastic paraplegia 20 protein; Trans-activated by hepatitis C virus core protein 1
• Entrez Gene (Human): 23111.0
• SwissProt (Human): Q8N0X7
• Purity: > 97%
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SPG20 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Storage/Stability: Shipped at 4 °C. Store at -20 °C for one year.
• Datasheet: http://www.cohesionbio.com/download/CRH8005.pdf